HighTide Therapeutics, Inc.
君圣泰医药
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2511)

LATE-BREAKING ASN 2025 | HIGHTIDE THERAPEUTICS PRESENTS EVIDENCE OF RENAL BENEFIT WITH HTD1801

This announcement is made by HighTide Therapeutics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors (the "**Board**") of the Company announces that HighTide Therapeutics presented the evidence of kidney benefit with HTD1801 in patients with mild renal impairment at the 58th Annual Meeting of the American Society of Nephrology (ASN) in Houston, US.

The clinical evidence that a therapy may benefit patients with chronic kidney disease (CKD) by improving the eGFR trajectory and recovering kidney function at the earliest stages of CKD

HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) with a dual mechanism of AMPK activation and NLRP3 inhibition to address the residual risks associated with cardiovascular-kidney-metabolic (CKM) diseases.

Data from two randomized, double-blind, placebo-controlled Phase III studies of HTD1801 in patients with type 2 diabetes mellitus (T2DM) (SYMPHONY 1 & 2; N=956) were pooled for analysis. Post-hoc subgroup analyses of the pooled data evaluated the effect of HTD1801 on renal function using eGFR trajectory. Mild renal impairment was defined as baseline eGFR 60-90 ml/min/1.73m^2, and hyperfiltration was defined as baseline eGFR ≥120 ml/min/1.73m^2.

In patients with mild renal impairment, treatment with HTD1801 was associated with a meaningful improvement in eGFR compared with placebo, resulting in a positive eGFR slope over time. In patients with hyperfiltration, HTD1801 led to a reduction in eGFR relative to placebo, consistent with a normalization of renal function. HTD1801 treatment demonstrated no clinically relevant effects on blood pressure, serum sodium or potassium.

Abstract Title: Evidence of Kidney Benefit with HTD1801 in Patients with Mild Renal Impairment
Presentation Number: TH-PO1190
Presentation Date/Time: 10:00 AM-12:00 PM November 6, 2025
Format: Poster Presentation
Presenting Author: Filip Surmont, MD; Leili Gao, MD; Kui Liu, MD; Leigh MacConell, PhD, Meng Yu, MSc; Liping Liu, PhD; Linong Ji, MD, on behalf of the SYMPHONY Investigators

About HTD1801

HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular-kidney-metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management.

About HighTide Therapeutics

HighTide Therapeutics, Inc. (2511.HK) is a biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for chronic metabolic diseases, with a strategic emphasis to address the residual risks of cardiovascular-kidney-metabolic (CKM) syndrome. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across chronic metabolic diseases. The company's lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China's *National Major Science and Technology Project for Significant New Drug Development*.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that HTD1801 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, November 7, 2025

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. LI Jin and Mr. HUNG Tak Wai as independent non-executive Directors.